| |
| |
|
| Insider
Information: |
Vessey Rupert |
| Relationship: |
EVP & President, Resea... |
| City: |
Summit |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
55,636 |
|
|
Indirect Shares
|
656 |
|
|
| Direct
Value |
$2,646,745 |
|
|
|
Indirect Value
|
$29,422 |
|
|
| Total
Shares |
56,292 |
|
|
| Total
Value |
$2,676,167 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
6
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 9.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2023-10-26 |
7,885 |
2019-07-01 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
EVP & President, Resea... |
2023-05-03 |
47,751 |
2023-05-03 |
656 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TECH |
Techne Corp |
Director |
– • – |
2023-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,625 |
7,885 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-05-03 |
4 |
S |
$67.06 |
$3,378,818 |
D/D |
(50,385) |
47,751 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
D |
$65.71 |
$2,529,704 |
D/D |
(38,498) |
98,136 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,326 |
123,701 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP & President, Research |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,935 |
118,263 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
65,871 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-12-02 |
4 |
D |
$81.13 |
$364,923 |
D/D |
(4,498) |
61,373 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
S |
$78.88 |
$3,621,381 |
D/D |
(45,910) |
57,079 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
OE |
$38.41 |
$3,067,529 |
D/D |
52,604 |
102,989 |
0 |
- |
|
| TECH |
Techne Corp |
|
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
338 |
1,565 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-16 |
4 |
OE |
$38.41 |
$2,696,612 |
D/D |
47,305 |
93,613 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-16 |
4 |
S |
$69.23 |
$5,162,973 |
D/D |
(74,559) |
50,385 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-10 |
4 |
D |
$68.42 |
$598,743 |
D/D |
(8,751) |
77,639 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,859 |
82,091 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,247 |
81,213 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-01 |
4 |
D |
$68.63 |
$707,095 |
D/D |
(10,303) |
69,284 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,350 |
79,587 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-02-04 |
4 |
D |
$64.99 |
$85,267 |
D/D |
(1,312) |
56,237 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2022-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,593 |
57,549 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,029 |
76,989 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-31 |
4 |
D |
$62.35 |
$1,436,108 |
D/D |
(23,033) |
53,956 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-16 |
4 |
S |
$61.99 |
$1,196,252 |
D/D |
(19,298) |
31,960 |
0 |
% |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-02 |
4 |
D |
$55.41 |
$249,234 |
D/D |
(4,498) |
51,258 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
55,756 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
• – – |
2021-07-30 |
4 |
OE |
$44.70 |
$8,830,108 |
D/D |
150,967 |
187,617 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
